VHL, the story of a tumour suppressor gene
暂无分享,去创建一个
[1] J. Brugarolas. Molecular genetics of clear-cell renal cell carcinoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] G. Mills,et al. Genetic and pharmacological strategies to refunctionalize the von Hippel Lindau R167Q mutant protein. , 2014, Cancer research.
[3] N. Rosenfeld,et al. Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma , 2014, Genes, chromosomes & cancer.
[4] J. Palmblad,et al. Genetic Basis of Congenital Erythrocytosis: Mutation Update and Online Databases , 2014, Human mutation.
[5] F. Girodon,et al. Molecular study of congenital erythrocytosis in 70 unrelated patients revealed a potential causal mutation in less than half of the cases (Where is/are the missing gene(s)?) , 2013, European journal of haematology.
[6] M. Climent,et al. Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] Steven J. M. Jones,et al. Comprehensive molecular characterization of clear cell renal cell carcinoma , 2013, Nature.
[8] H. Aburatani,et al. Integrated molecular analysis of clear-cell renal cell carcinoma , 2013, Nature Genetics.
[9] S. Signoretti,et al. The Role of Aberrant VHL/HIF Pathway Elements in Predicting Clinical Outcome to Pazopanib Therapy in Patients with Metastatic Clear-Cell Renal Cell Carcinoma , 2013, Clinical Cancer Research.
[10] W. Krek,et al. Genetic deletion of the long isoform of the von Hippel-Lindau tumour suppressor gene product alters microtubule dynamics. , 2013, European journal of cancer.
[11] The Cancer Genome Atlas Research Network. COMPREHENSIVE MOLECULAR CHARACTERIZATION OF CLEAR CELL RENAL CELL CARCINOMA , 2013, Nature.
[12] J. Prchal,et al. Novel homozygous VHL mutation in exon 2 is associated with congenital polycythemia but not with cancer. , 2013, Blood.
[13] Han Liu,et al. Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma. , 2013, European urology.
[14] Gang Wang,et al. Activation of HIF2α in kidney proximal tubule cells causes abnormal glycogen deposition but not tumorigenesis. , 2013, Cancer research.
[15] C. Sander,et al. Adverse Outcomes in Clear Cell Renal Cell Carcinoma with Mutations of 3p21 Epigenetic Regulators BAP1 and SETD2: A Report by MSKCC and the KIRC TCGA Research Network , 2013, Clinical Cancer Research.
[16] S. Nekhai,et al. The phenotype of polycythemia due to Croatian homozygous VHL (571C>G:H191D) mutation is different from that of Chuvash polycythemia (VHL 598C>T:R200W) , 2013, Haematologica.
[17] Rui Chen,et al. Allosteric Inhibition of Hypoxia Inducible Factor-2 with Small Molecules , 2013, Nature chemical biology.
[18] M. Malumbres,et al. HIF2α acts as an mTORC1 activator through the amino acid carrier SLC7A5. , 2012, Molecular cell.
[19] W. Linehan,et al. Lack of a functional VHL gene product sensitizes renal cell carcinoma cells to the apoptotic effects of the protein synthesis inhibitor verrucarin A. , 2012, Neoplasia.
[20] Klaas Kok,et al. Targeted exome sequencing in clear cell renal cell carcinoma tumors suggests aberrant chromatin regulation as a crucial step in ccRCC development , 2012, Human mutation.
[21] N. Grishin,et al. BAP1 loss defines a new class of renal cell carcinoma , 2012, Nature Genetics.
[22] T. Cenci,et al. Von hippel-lindau disease and erythrocytosis. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] C. Porta,et al. Treatment selection in metastatic renal cell carcinoma: expert consensus , 2012, Nature Reviews Clinical Oncology.
[24] G. Semenza. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. , 2012, Trends in pharmacological sciences.
[25] P. A. Futreal,et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.
[26] G. Mills,et al. Agents That Stabilize Mutated von Hippel–Lindau (VHL) Protein , 2012, Journal of biomolecular screening.
[27] G. Mills,et al. Results of a high-throughput screen to identify compounds that modulate VHL proteostasis. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] M. Zhou,et al. The von Hippel–Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C , 2012, Oncogene.
[29] Yasushi Totoki,et al. Whole-exome sequencing of human pancreatic cancers and characterization of genomic instability caused by MLH1 haploinsufficiency and complete deficiency. , 2012, Genome research.
[30] Huanming Yang,et al. Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma , 2011, Nature Genetics.
[31] Brian Keith,et al. HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression , 2011, Nature Reviews Cancer.
[32] Gang Wang,et al. Generation of a mouse model of Von Hippel-Lindau kidney disease leading to renal cancers by expression of a constitutively active mutant of HIF1α. , 2011, Cancer research.
[33] 吳國瑞,et al. Interplay between HDAC3 and WDR5 Is Essential for Hypoxia-Induced Epithelial-Mesenchymal Transition , 2011 .
[34] G. Semenza. Oxygen sensing, homeostasis, and disease. , 2011, The New England journal of medicine.
[35] P. Sutphin,et al. Targeting GLUT1 and the Warburg Effect in Renal Cell Carcinoma by Chemical Synthetic Lethality , 2011, Science Translational Medicine.
[36] William Y. Kim,et al. Loss of JAK2 regulation via a heterodimeric VHL-SOCS1 E3 ubiquitin ligase underlies Chuvash polycythemia , 2011, Nature Medicine.
[37] H. Moch,et al. VHL gene mutations and their effects on hypoxia inducible factor HIFα: identification of potential driver and passenger mutations. , 2011, Cancer research.
[38] Jiannis Ragoussis,et al. High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq. , 2011, Blood.
[39] Rameen Beroukhim,et al. Genetic and functional studies implicate HIF1α as a 14q kidney cancer suppressor gene. , 2011, Cancer discovery.
[40] S. Richard,et al. von Hippel–Lindau disease: A clinical and scientific review , 2011, European Journal of Human Genetics.
[41] K. Gustafson,et al. Identification and evaluation of soft coral diterpenes as inhibitors of HIF-2α induced gene expression. , 2011, Bioorganic & medicinal chemistry letters.
[42] P. A. Futreal,et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma , 2010, Nature.
[43] G. Semenza. mechanisms of disease Oxygen Sensing , Homeostasis , and Disease , 2011 .
[44] W. Linehan,et al. A new hypoxia inducible factor-2 inhibitory pyrrolinone alkaloid from roots and stems of Piper sarmentosum. , 2011, Chemical & pharmaceutical bulletin.
[45] Gaudenz Danuser,et al. Quantitative image analysis identifies pVHL as a key regulator of microtubule dynamic instability , 2010, The Journal of cell biology.
[46] S. Welford,et al. Renal Oxygenation Suppresses VHL Loss-Induced Senescence That Is Caused by Increased Sensitivity to Oxidative Stress , 2010, Molecular and Cellular Biology.
[47] R. Bukowski,et al. Biomarkers Predicting Outcome in Patients with Advanced Renal Cell Carcinoma: Results from Sorafenib Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial , 2010, Clinical Cancer Research.
[48] S. Lowe,et al. HIF-1 antagonizes p53-mediated apoptosis through a secreted neuronal tyrosinase , 2010, Nature.
[49] Gerben Duns,et al. Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma. , 2010, Cancer research.
[50] A. V. D. van den Ouweland,et al. Genetic analysis of von Hippel‐Lindau disease , 2010, Human mutation.
[51] L. Gossage,et al. Alterations in VHL as potential biomarkers in renal-cell carcinoma , 2010, Nature Reviews Clinical Oncology.
[52] E. Morrisey,et al. The von Hippel-Lindau Chuvash mutation promotes pulmonary hypertension and fibrosis in mice. , 2010, The Journal of clinical investigation.
[53] A. Pantuck,et al. NF-kappaB-dependent plasticity of the epithelial to mesenchymal transition induced by Von Hippel-Lindau inactivation in renal cell carcinomas. , 2010, Cancer research.
[54] Gurpreet W. Tang,et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes , 2009, Nature.
[55] W. Gregory,et al. Analysis of VHL Gene Alterations and their Relationship to Clinical Parameters in Sporadic Conventional Renal Cell Carcinoma , 2009, Clinical Cancer Research.
[56] M. Ohh,et al. Suppression of hypoxia-inducible factor 2alpha restores p53 activity via Hdm2 and reverses chemoresistance of renal carcinoma cells. , 2009, Cancer research.
[57] G. Calin,et al. Emerging roles of microRNAs in the molecular responses to hypoxia. , 2009, Current pharmaceutical design.
[58] Huafeng Zhang,et al. Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization , 2009, Proceedings of the National Academy of Sciences.
[59] A. McNeill,et al. Genotype–phenotype correlations in VHL exon deletions , 2009, American journal of medical genetics. Part A.
[60] H. Moch,et al. VHL loss causes spindle misorientation and chromosome instability , 2009, Nature Cell Biology.
[61] M. Zeegers,et al. Analysis of Germline Variants in CDH1, IGFBP3, MMP1, MMP3, STK15 and VEGF in Familial and Sporadic Renal Cell Carcinoma , 2009, PloS one.
[62] F. V. van Eeden,et al. Zebrafish mutants in the von Hippel-Lindau tumor suppressor display a hypoxic response and recapitulate key aspects of Chuvash polycythemia. , 2009, Blood.
[63] E. Rankin,et al. Hypoxia-Inducible Factor 2 Regulates Hepatic Lipid Metabolism , 2009, Molecular and Cellular Biology.
[64] H. Neumann,et al. Alu‐Alu recombination underlies the vast majority of large VHL germline deletions: Molecular characterization and genotype–phenotype correlations in VHL patients , 2009, Human mutation.
[65] Bin Tean Teh,et al. Somatic mutations of the histone H3K27 demethylase, UTX, in human cancer , 2009, Nature Genetics.
[66] Wei Li,et al. Integrative analysis of HIF binding and transactivation reveals its role in maintaining histone methylation homeostasis , 2009, Proceedings of the National Academy of Sciences.
[67] D. Jacqmin,et al. von Hippel-Lindau tumor suppressor gene-dependent mRNA stabilization of the survival factor parathyroid hormone-related protein in human renal cell carcinoma by the RNA-binding protein HuR. , 2009, Carcinogenesis.
[68] Kevin H. Gardner,et al. Artificial ligand binding within the HIF2α PAS-B domain of the HIF2 transcription factor , 2009, Proceedings of the National Academy of Sciences.
[69] D. Shukla,et al. Regulation of renal epithelial tight junctions by the von Hippel-Lindau tumor suppressor gene involves occludin and claudin 1 and is independent of E-cadherin. , 2008, Molecular biology of the cell.
[70] K. Flaherty,et al. HIF- α effects on c-Myc distinguish two subtypes of sporadic VHL -deficient clear cell renal carcinoma , 2009 .
[71] Jens Vilstrup Johansen,et al. The Histone Demethylases JMJD1A and JMJD2B Are Transcriptional Targets of Hypoxia-inducible Factor HIF* , 2008, Journal of Biological Chemistry.
[72] T. Golub,et al. Small-molecule inhibitors of HIF-2a translation link its 5'UTR iron-responsive element to oxygen sensing. , 2008, Molecular cell.
[73] P. Ratcliffe,et al. Regulation of Jumonji-domain-containing histone demethylases by hypoxia-inducible factor (HIF)-1alpha. , 2008, The Biochemical journal.
[74] Brian Keith,et al. HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. , 2008, Cancer cell.
[75] W. Kaelin,et al. Kinase requirements in human cells: III. Altered kinase requirements in VHL−/− cancer cells detected in a pilot synthetic lethal screen , 2008, Proceedings of the National Academy of Sciences.
[76] E. Rankin,et al. Hypoxia-inducible factor-2 regulates vascular tumorigenesis in mice , 2008, Oncogene.
[77] F. Waldman,et al. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. , 2008, The Journal of urology.
[78] P. Sutphin,et al. A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy. , 2008, Cancer cell.
[79] R. Burk,et al. Downregulation of integrins by von Hippel-Lindau (VHL) tumor suppressor protein is independent of VHL-directed hypoxia-inducible factor alpha degradation. , 2008, Biochemistry and cell biology = Biochimie et biologie cellulaire.
[80] S A Forbes,et al. The Catalogue of Somatic Mutations in Cancer (COSMIC) , 2008, Current protocols in human genetics.
[81] S. Signoretti,et al. VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400 , 2008, Nature Cell Biology.
[82] Svetlana V. Harbaugh,et al. The von Hippel-Lindau Tumor Suppressor Protein and Egl-9-Type Proline Hydroxylases Regulate the Large Subunit of RNA Polymerase II in Response to Oxidative Stress , 2008, Molecular and Cellular Biology.
[83] A. Pause,et al. Collagen matrix assembly is driven by the interaction of von Hippel–Lindau tumor suppressor protein with hydroxylated collagen IV alpha 2 , 2008, Oncogene.
[84] S. Signoretti,et al. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. , 2007, Clinical genitourinary cancer.
[85] W. Rathmell,et al. von Hippel-Lindau mutation in mice recapitulates Chuvash polycythemia via hypoxia-inducible factor-2alpha signaling and splenic erythropoiesis. , 2007, The Journal of clinical investigation.
[86] B. Ebert,et al. pVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappaB agonist Card9 by CK2. , 2007, Molecular cell.
[87] P. Dervan,et al. Modulating hypoxia-inducible transcription by disrupting the HIF-1-DNA interface. , 2007, ACS chemical biology.
[88] W. Krek,et al. The VHL Tumor Suppressor: Riding Tandem with GSK3β in Primary Cilium Maintenance , 2007, Cell cycle.
[89] J. M. García-Sagredo,et al. Loss of the actin regulator HSPC300 results in clear cell renal cell carcinoma protection in Von Hippel‐Lindau patients , 2007, Human mutation.
[90] Yoji Andrew Minamishima,et al. Hypoxia-Inducible Factor Linked to Differential Kidney Cancer Risk Seen with Type 2A and Type 2B VHL Mutations , 2007, Molecular and Cellular Biology.
[91] P. Ratcliffe,et al. Interaction of Hydroxylated Collagen IV with the von Hippel-Lindau Tumor Suppressor* , 2007, Journal of Biological Chemistry.
[92] E. Rankin,et al. Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo. , 2007, The Journal of clinical investigation.
[93] R. Johnson,et al. Acute postnatal ablation of Hif-2α results in anemia , 2007, Proceedings of the National Academy of Sciences.
[94] E. Maher,et al. Genotype–phenotype correlations in von Hippel‐Lindau disease , 2004, Human mutation.
[95] S. Richard,et al. Somatic von Hippel-Lindau (VHL) gene analysis and clinical outcome under antiangiogenic treatment in metastatic renal cell carcinoma: preliminary results , 2007, Targeted Oncology.
[96] P. Dervan,et al. Exploring the limits of benzimidazole DNA-binding oligomers for the hypoxia inducible factor (HIF) site. , 2006, Bioorganic & medicinal chemistry.
[97] C. Brinckerhoff,et al. Tumor cell invasion of von Hippel Lindau renal cell carcinoma cells is mediated by membrane type-1 matrix metalloproteinase , 2006, Molecular Cancer.
[98] H. Zentgraf,et al. The von Hippel-Lindau tumor suppressor protein controls ciliogenesis by orienting microtubule growth , 2006, The Journal of cell biology.
[99] G. Berx,et al. VHL Promotes E2 Box-Dependent E-Cadherin Transcription by HIF-Mediated Regulation of SIP1 and Snail , 2006, Molecular and Cellular Biology.
[100] B. Ebert,et al. Failure to prolyl hydroxylate hypoxia‐inducible factor α phenocopies VHL inactivation in vivo , 2006 .
[101] W. Kaelin,et al. Molecular pathways in renal cell carcinoma--rationale for targeted treatment. , 2006, Seminars in oncology.
[102] K. Chew,et al. Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel‐Lindau gene status , 2006, BJU international.
[103] H. Youn,et al. The Positive Regulation of p53 by the Tumor Suppressor VHL , 2006, Cell cycle.
[104] W. Linehan,et al. Development of a Cell-Based Reporter Assay for Screening of Inhibitors of Hypoxia-Inducible Factor 2-Induced Gene Expression , 2006, Journal of biomolecular screening.
[105] Claudio R. Thoma,et al. Priming-Dependent Phosphorylation and Regulation of the Tumor Suppressor pVHL by Glycogen Synthase Kinase 3 , 2006, Molecular and Cellular Biology.
[106] R. Burk,et al. Primary cilium formation requires von hippel-lindau gene function in renal-derived cells. , 2006, Cancer research.
[107] M. Tran,et al. Formation of primary cilia in the renal epithelium is regulated by the von Hippel-Lindau tumor suppressor protein. , 2006, Journal of the American Society of Nephrology : JASN.
[108] M. Ashcroft,et al. Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway. , 2006, Cancer research.
[109] E. Cho,et al. p53 stabilization and transactivation by a von Hippel-Lindau protein. , 2006, Molecular cell.
[110] R. Johnson,et al. pVHL Function Is Essential for Endothelial Extracellular Matrix Deposition , 2006, Molecular and Cellular Biology.
[111] E. Rankin,et al. Renal cyst development in mice with conditional inactivation of the von Hippel-Lindau tumor suppressor. , 2006, Cancer research.
[112] M. Ohh,et al. Characterization of a von Hippel Lindau pathway involved in extracellular matrix remodeling, cell invasion, and angiogenesis. , 2006, Cancer research.
[113] P. Jemth,et al. Renal cell carcinoma risk in type 2 von Hippel–Lindau disease correlates with defects in pVHL stability and HIF-1α interactions , 2006, Oncogene.
[114] D. Mukhopadhyay,et al. Role of elongin-binding domain of von hippel lindau gene product on HuR-mediated VPF/VEGF mRNA stability in renal cell carcinoma , 2005, Oncogene.
[115] W. Kaelin. The Concept of Synthetic Lethality in the Context of Anticancer Therapy , 2005, Nature Reviews Cancer.
[116] W. Kaelin,et al. Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. , 2005, Cancer cell.
[117] G. Semenza,et al. Stromal Cell–Derived Factor-1α and CXCR4 Expression in Hemangioblastoma and Clear Cell-Renal Cell Carcinoma: von Hippel-Lindau Loss-of-Function Induces Expression of a Ligand and Its Receptor , 2005 .
[118] Patrick H. Maxwell,et al. Contrasting Properties of Hypoxia-Inducible Factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-Associated Renal Cell Carcinoma , 2005, Molecular and Cellular Biology.
[119] J. Frydman,et al. Folding and Quality Control of the VHL Tumor Suppressor Proceed through Distinct Chaperone Pathways , 2005, Cell.
[120] C. Vinson. A Rationally Designed Small Molecule That Inhibits the HIF-1α–ARNT Heterodimer from Binding to DNA in Vivo , 2005, Science's STKE.
[121] Joon-Oh Park,et al. Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma. , 2005, Oncology reports.
[122] E. Rankin,et al. Inactivation of the Arylhydrocarbon Receptor Nuclear Translocator (Arnt) Suppresses von Hippel-Lindau Disease-Associated Vascular Tumors in Mice , 2005, Molecular and Cellular Biology.
[123] J. Richardson,et al. HIF-2alpha regulates murine hematopoietic development in an erythropoietin-dependent manner. , 2005, Blood.
[124] M. Rettig,et al. VHL expression in renal cell carcinoma sensitizes to bortezomib (PS-341) through an NF-κB-dependent mechanism , 2005, Oncogene.
[125] C. Brinckerhoff,et al. Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2α in von Hippel–Lindau renal cell carcinoma , 2005, Oncogene.
[126] A. Fersht,et al. Binding of Natively Unfolded HIF-1α ODD Domain to p53 , 2005 .
[127] P. E. V. Hippel. Über eine sehr seltene Erkrankung der Netzhaut , 1904, Albrecht von Graefes Archiv für Ophthalmologie.
[128] G. Semenza,et al. Stromal Cell – Derived Factor-1 A and CXCR 4 Expression in Hemangioblastoma and Clear Cell-Renal Cell Carcinoma : von Hippel-Lindau Loss-of-Function Induces Expression of a Ligand and Its Receptor , 2005 .
[129] Martin S. Taylor,et al. Genetic Analysis of Pathways Regulated by the von Hippel-Lindau Tumor Suppressor in Caenorhabditis elegans , 2004, PLoS biology.
[130] C. Junien,et al. Genotype–phenotype correlation in von Hippel‐Lindau families with renal lesions , 2004, Human mutation.
[131] 三原 忠紘,et al. てんかん治療の Expert Consensus , 2004 .
[132] J. Klco,et al. pVHL Modification by NEDD8 Is Required for Fibronectin Matrix Assembly and Suppression of Tumor Development , 2004, Molecular and Cellular Biology.
[133] O. Iliopoulos,et al. Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors. , 2004, Molecular cancer research : MCR.
[134] F. Holstege,et al. Fibronectin is a hypoxia‐independent target of the tumor suppressor VHL , 2004, FEBS letters.
[135] P. Albert,et al. Solid renal tumor severity in von Hippel Lindau disease is related to germline deletion length and location , 2004, Human mutation.
[136] P. Choyke,et al. Von Hippel-Lindau (VHL) disease: distinct phenotypes suggest more than one mutant allele at the VHL locus , 1991, Human Genetics.
[137] K. Tory,et al. Molecular genetic investigations of the mechanism of tumourigenesis in von Hippel-Lindau disease: analysis of allele loss in VHL tumours , 2004, Human Genetics.
[138] Brian Keith,et al. Differential Roles of Hypoxia-Inducible Factor 1α (HIF-1α) and HIF-2α in Hypoxic Gene Regulation , 2003, Molecular and Cellular Biology.
[139] W. Kaelin,et al. Inhibition of HIF2α Is Sufficient to Suppress pVHL-Defective Tumor Growth , 2003, PLoS biology.
[140] L. Gunaratnam,et al. Hypoxia Inducible Factor Activates the Transforming Growth Factor-α/Epidermal Growth Factor Receptor Growth Stimulatory Pathway in VHL-/- Renal Cell Carcinoma Cells* , 2003, Journal of Biological Chemistry.
[141] M. Ohh,et al. The von Hippel-Lindau tumor suppressor protein sensitizes renal cell carcinoma cells to tumor necrosis factor-induced cytotoxicity by suppressing the nuclear factor-kappaB-dependent antiapoptotic pathway. , 2003, Cancer research.
[142] M. Gorospe,et al. Influence of the RNA-Binding Protein HuR in pVHL-Regulated p53 Expression in Renal Carcinoma Cells , 2003, Molecular and Cellular Biology.
[143] H. Moch,et al. Chemokine receptor CXCR4 downregulated by von Hippel–Lindau tumour suppressor pVHL , 2003, Nature.
[144] H. Tabuchi,et al. Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through Hypoxia-inducible factor , 2003, Oncogene.
[145] J. Klco,et al. Gene expression profiling in a renal cell carcinoma cell line: dissecting VHL and hypoxia-dependent pathways. , 2003, Molecular cancer research : MCR.
[146] R. Conaway,et al. von Hippel–Lindau protein binds hyperphosphorylated large subunit of RNA polymerase II through a proline hydroxylation motif and targets it for ubiquitination , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[147] J. Jelinek,et al. Mutations in the VHL gene in sporadic apparently congenital polycythemia. , 2003, Blood.
[148] W. Krek,et al. Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL , 2003, Nature Cell Biology.
[149] David Mole,et al. Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia , 2002, Nature Genetics.
[150] J. Strauchen. Germ-line mutations in nonsyndromic pheochromocytoma. , 2002, The New England journal of medicine.
[151] R. Houlston,et al. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease. , 2002, Cancer research.
[152] Christopher J. Schofield,et al. Structural basis for the recognition of hydroxyproline in HIF-1α by pVHL , 2002, Nature.
[153] Charles C Wykoff,et al. HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. , 2002, Cancer cell.
[154] Richard D Klausner,et al. VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells. , 2002, Cancer research.
[155] F. Sánchez‐Madrid,et al. Role of the von Hippel-Lindau tumor suppressor gene in the formation of beta1-integrin fibrillar adhesions. , 2002, Cancer research.
[156] M. Ivan,et al. Structure of an HIF-1α-pVHL Complex: Hydroxyproline Recognition in Signaling , 2002, Science.
[157] Richard D Klausner,et al. The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. , 2002, Cancer cell.
[158] Mirna Lechpammer,et al. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. , 2002, Cancer cell.
[159] L. Khachigian,et al. von Hippel‐Lindau tumor suppressor protein represses platelet‐derived growth factor B‐chain gene expression via the Sp1 binding element in the proximal PDGF‐B promoter , 2002, Journal of cellular biochemistry.
[160] S. McKnight,et al. A Conserved Family of Prolyl-4-Hydroxylases That Modify HIF , 2001, Science.
[161] S. White,et al. HIF-1α binding to VHL is regulated by stimulus-sensitive proline hydroxylation , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[162] P. Ratcliffe,et al. Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. , 2001, Human molecular genetics.
[163] J. Zentner,et al. Reconsideration of biallelic inactivation of theVHL tumour suppressor gene in hemangioblastomas of the central nervous system , 2001, Journal of neurology, neurosurgery, and psychiatry.
[164] M. Ivan,et al. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. , 2001, Human molecular genetics.
[165] M. Ivan,et al. HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O2 Sensing , 2001, Science.
[166] Michael I. Wilson,et al. Targeting of HIF-α to the von Hippel-Lindau Ubiquitylation Complex by O2-Regulated Prolyl Hydroxylation , 2001, Science.
[167] Eamonn R. Maher,et al. Hypoxia Inducible Factor-α Binding and Ubiquitylation by the von Hippel-Lindau Tumor Suppressor Protein* , 2000, The Journal of Biological Chemistry.
[168] L. Poellinger,et al. Mechanism of regulation of the hypoxia‐inducible factor‐1α by the von Hippel‐Lindau tumor suppressor protein , 2000, The EMBO journal.
[169] R. Burk,et al. Elongin BC complex prevents degradation of von Hippel-Lindau tumor suppressor gene products. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[170] M. Ivan,et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel–Lindau protein , 2000, Nature Cell Biology.
[171] D. Mukhopadhyay,et al. An important von Hippel-Lindau tumor suppressor domain mediates Sp1-binding and self-association. , 1999, Biochemical and biophysical research communications.
[172] V. Thulasiraman,et al. Formation of the VHL-elongin BC tumor suppressor complex is mediated by the chaperonin TRiC. , 1999, Molecular cell.
[173] R. Klausner,et al. Identification of the von Hippel-lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[174] T. Shuin,et al. Direct interaction of the beta-domain of VHL tumor suppressor protein with the regulatory domain of atypical PKC isotypes. , 1999, Biochemical and biophysical research communications.
[175] M. Gstaiger,et al. The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity. , 1999, Genes & development.
[176] C. Wykoff,et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis , 1999, Nature.
[177] S. Elledge,et al. Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. , 1999, Science.
[178] W. Kaelin,et al. Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. , 1999, Science.
[179] B. Seizinger,et al. Alternate choice of initiation codon produces a biologically active product of the von Hippel Lindau gene with tumor suppressor activity , 1999, Oncogene.
[180] C. Junien,et al. Mutations of the VHL gene in sporadic renal cell carcinoma: Definition of a risk factor for VHL patients to develop an RCC , 1999, Human mutation.
[181] T. Fojo,et al. Inhibitors of transcription, proteasome inhibitors, and DNA-damaging drugs differentially affect feedback of p53 degradation. , 1998, Experimental cell research.
[182] A. Webster,et al. An analysis of phenotypic variation in the familial cancer syndrome von Hippel-Lindau disease: evidence for modifier effects. , 1998, American journal of human genetics.
[183] W. Kaelin,et al. pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[184] R. Burk,et al. A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[185] S. Clifford,et al. Inactivation of the von Hippel–Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: Evidence for a VHL‐independent pathway in clear cell renal tumourigenesis , 1998 .
[186] D. Louis,et al. The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. , 1998, Molecular cell.
[187] R. Klausner,et al. The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[188] W. Kaelin,et al. Regulation of Hypoxia-Inducible mRNAs by the von Hippel-Lindau Tumor Suppressor Protein Requires Binding to Complexes Containing Elongins B/C and Cul2 , 1998, Molecular and Cellular Biology.
[189] V. Sukhatme,et al. Transforming Growth Factor α Is a Target for the Von Hippel-Lindau Tumor Suppressor , 1998 .
[190] S. Clifford,et al. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis. , 1998, Genes, chromosomes & cancer.
[191] K. Plate,et al. Coexpression of erythropoietin and vascular endothelial growth factor in nervous system tumors associated with von Hippel-Lindau tumor suppressor gene loss of function. , 1998, Blood.
[192] Christophe Béroud,et al. Software and database for the analysis of mutations in the VHL gene , 1998, Nucleic Acids Res..
[193] D. Mukhopadhyay,et al. The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity , 1997, Molecular and cellular biology.
[194] E. van den Berg,et al. Analysis of multiple renal cell adenomas and carcinomas suggests allelic loss at 3p21 to be a prerequisite for malignant development , 1997, Genes, chromosomes & cancer.
[195] R. Klausner,et al. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[196] R. Klausner,et al. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[197] W. Kaelin,et al. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[198] G. Reifenberger,et al. MUTATION OF THE VON HIPPEL–LINDAU TUMOUR SUPPRESSOR GENE IN CAPILLARY HAEMANGIOBLASTOMAS OF THE CENTRAL NERVOUS SYSTEM , 1996, The Journal of pathology.
[199] S. Chew,et al. Mutations in the RET proto-oncogene and the von Hippel-Lindau disease tumour suppressor gene in sporadic and syndromic phaeochromocytomas. , 1995, Journal of medical genetics.
[200] Fan,et al. Cellular proteins that bind the von Hippel-Lindau disease gene product: mapping of binding domains and the effect of missense mutations. , 1995, Cancer research.
[201] D. Duan,et al. Inhibition of transcription elongation by the VHL tumor suppressor protein , 1995, Science.
[202] A. Kibel,et al. Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C , 1995, Science.
[203] T. Shuin,et al. [Results of mutation analyses of von Hippel-Lindau disease gene in Japanese patients: comparison with results in United States and United Kingdom]. , 1995, Hinyokika kiyo. Acta urologica Japonica.
[204] A. Kibel,et al. Tumour suppression by the human von Hippel-Lindau gene product , 1995, Nature Medicine.
[205] K. Plate,et al. Up-regulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic hemangioblastomas. , 1995, Cancer research.
[206] W. Linehan,et al. Germline mutations in the von Hippel–Lindau disease tumor suppressor gene: Correlations with phenotype , 1995, Human mutation.
[207] M. Ferguson-Smith,et al. Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma. , 1994, Human molecular genetics.
[208] B. Seizinger,et al. Germ-line mutations in the von Hippel-Lindau tumor-suppressor gene are similar to somatic von Hippel-Lindau aberrations in sporadic renal cell carcinoma. , 1994, American journal of human genetics.
[209] T. Sugimura,et al. Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. , 1994, Cancer research.
[210] T. Sugiyama,et al. Frequent overexpression of vascular endothelial growth factor gene in human renal cell carcinoma. , 1994, The Tohoku journal of experimental medicine.
[211] J. Brooks,et al. Mutations of the VHL tumour suppressor gene in renal carcinoma , 1994, Nature Genetics.
[212] J. Gnarra,et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. , 1993, Science.
[213] F. Hartl,et al. Function in protein folding of TRiC, a cytosolic ring complex containing TCP‐1 and structurally related subunits. , 1992, The EMBO journal.
[214] O. Wiestler,et al. Clustering of features of von Hippel-Lindau syndrome: evidence for a complex genetic locus , 1991, The Lancet.
[215] M. Ferguson-Smith,et al. Statistical analysis of the two stage mutation model in von Hippel-Lindau disease, and in sporadic cerebellar haemangioblastoma and renal cell carcinoma. , 1990, Journal of medical genetics.
[216] N. Casadevall,et al. Tumor cells are the site of erythropoietin synthesis in human renal cancers associated with polycythemia. , 1990, Blood.
[217] Y. Nakamura,et al. Specific genetic change in tumors associated with von Hippel-Lindau disease. , 1989, Journal of the National Cancer Institute.
[218] H. Brauch,et al. Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma , 1988, Nature.
[219] G. Johnson,et al. Von Hippel-Lindau disease in a Newfoundland kindred. , 1986, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[220] N. Sobol,et al. PRELIMINARY RESULTS , 2004 .
[221] A. Knudson. Mutation and cancer: statistical study of retinoblastoma. , 1971, Proceedings of the National Academy of Sciences of the United States of America.
[222] K. Melmon,et al. Lindau's disease: Review of the literature and study of a large kindred , 1964 .
[223] A. Lindau. ZUR FRAGE DER ANGIOMATOSIS RETINæ UND IHRER HIRNKOMPLIKATIONEN , 1926 .